DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

Information source: Kocaeli University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Peripheral Vertigo

Intervention: Administration of 100 mg dimenhydrinate intravenous (Drug); 2 g piracetam intravenous (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Kocaeli University

Official(s) and/or principal investigator(s):
Nurettin Özgür Doğan, M.D., Assistant Professor, Principal Investigator, Affiliation: Kocaeli University


This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo. The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times:

- Numeric rating scale (1 to 10): Admission

- Numeric rating scale (1 to 10): After the study drug (No ambulation)*

- Numeric rating scale (1 to 10): After the study drug (Ambulation)*

- Ambulation refers to head movements or walking in the room, if applicable.

Clinical Details

Official title: Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Primary outcome: Change in numeric rating scale


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Presenting to emergency department with vertigo symptoms

- Adult patients (over 18)

- Agree to participate to study (understanding the study protocol and signing the

informed consent form) Exclusion Criteria:

- Patients under 18 years

- Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging

- Patient diagnosed with transient ischemic attack

- Pregnants

- Patients taking any analgesics or antihistaminic drugs last 24 hours

- Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines

- Patients who do not agree to participate to the study

Locations and Contacts

Kocaeli University, Kocaeli 41000, Turkey
Additional Information

Related publications:

Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz HJ. Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther. 2004 Jun;26(6):866-77.

Starting date: June 2013
Last updated: May 2, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017